SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a corporate overview on Monday, March 6th, 2023 at 1:30 pm ET.
A live webcast of the presentation will be available to view on the Events page in the Investors section of Bionano’s website.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.00 |
| Daily Change: | -0.13 -3.15 |
| Daily Volume: | 310,987 |
| Market Cap: | US$13.440M |
August 14, 2025 August 07, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
